(Q35185753)

7 August 2017

1 reference

title

Recent developments in the treatment of tuberculosis (English)

1 reference

7 August 2017

1 reference

Peter D O Davies

1

1 reference

PubMed ID

12882618

7 August 2017

W W Yew

series ordinal

2

1 reference

PubMed ID

12882618

7 August 2017

language of work or name

English

0 references

publication date

1 August 2003

1 reference

Expert Opinion on Investigational Drugs

7 August 2017

1 reference

7 August 2017

12

1 reference

7 August 2017

1297-1312

1 reference

7 August 2017

8

1 reference

Directly observed therapy for tuberculosis: history of an idea

7 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1297

A 62-dose, 6-month therapy for pulmonary and extrapulmonary tuberculosis. A twice-weekly, directly observed, and cost-effective regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1297

The results of 9-month isoniazid-rifampin therapy for pulmonary tuberculosis under program conditions in San Francisco

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1297

USPHS Tuberculosis Short-Course Chemotherapy Trial 21: effectiveness, toxicity, and acceptability. The report of final results

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1297

Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society and The Centers for Disease Control and Prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1297

American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1297

Fixed-dose combinations of antituberculous medications to prevent drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1297

When tuberculosis treatment fails. A social behavioral account of patient adherence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1297

Drug resistance and the selection of therapy for tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1297

Community based approaches to the control of multidrug resistant tuberculosis: introducing "DOTS-plus".

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1297

In-vitro activity of ofloxacin against Mycobacterium tuberculosis and its clinical efficacy in multiply resistant pulmonary tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1297

Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1297

Erasing the World's Slow Stain: Strategies to Beat Multidrug-Resistant Tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1297

Outcome of MDR-TB patients, 1983-1993. Prolonged survival with appropriate therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1297

Feasibility and cost-effectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1297

Randomized controlled trial of a drug regimen that includes ciprofloxacin for the treatment of pulmonary tuberculosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1297

Long-term safety of ofloxacin and ciprofloxacin in the treatment of mycobacterial infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1297

Safety profile of ciprofloxacin during long-term therapy for pulmonary tuberculosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1297

Adverse neurological reactions in patients with multidrug-resistant pulmonary tuberculosis after coadministration of cycloserine and ofloxacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1297

In vitro activity of the new difluorinated quinolone sparfloxacin (AT-4140) against Mycobacterium tuberculosis compared with activities of ofloxacin and ciprofloxacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1297

In-vitro activity of quinolones and macrolides against mycobacteria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1297

Sparfloxacin in the treatment of drug resistant tuberculosis or intolerance of first line therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1297

Moxifloxacin (BAY12-8039), a new 8-methoxyquinolone, is active in a mouse model of tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1297

Bactericidal activity of increasing daily and weekly doses of moxifloxacin in murine tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1297

In vitro and in vivo antimycobacterial activities of a new quinolone, DU-6859a

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1297

In vitro antibacterial spectrum of a new broad-spectrum 8-methoxy fluoroquinolone, gatifloxacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1297

In vitro and in vivo activities of gatifloxacin against Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1297

Emergence of fluoroquinolone-resistant tuberculosis in New York City.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1297

The need for new drugs against tuberculosis. Obstacles, opportunities, and next steps

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1297

Safety of an ofloxacin-based antitubercular regimen for the treatment of tuberculosis in patients with underlying chronic liver disease: a preliminary report

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1297

The role of fluoroquinolones in tuberculosis today

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1297

In vitro and in vivo activities of the benzoxazinorifamycin KRM-1648 against Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1297

Evaluation of rifalazil in long-term treatment regimens for tuberculosis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1297

Safety and bactericidal activity of rifalazil in patients with pulmonary tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1297

Development potential of rifalazil

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1297

Phase I pharmacokinetic study of a new 3-azinomethyl-rifamycin (rifametane) as compared to rifampicin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1297

In vivo activity of paromomycin against susceptible and multidrug-resistant Mycobacterium tuberculosis and M. avium complex strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1297

Early bactericidal activity of paromomycin (aminosidine) in patients with smear-positive pulmonary tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1297

Clarithromycin is inactive against Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1297

Identification of a novel oxazolidinone (U-100480) with potent antimycobacterial activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1297

Successful treatment of disseminated Mycobacterium chelonae infection with linezolid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1297

In vitro and in vivo activities of the nitroimidazole CGI 17341 against Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1297

In vitro activity of a novel antimycobacterial compound, N-octanesulfonylacetamide, and its effects on lipid and mycolic acid synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1297

Latest developments in gene transfer technology: achievements, perspectives, and controversies over therapeutic applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1297

Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1297

Combinatorial lead optimization of [1,2]-diamines based on ethambutol as potential antituberculosis preclinical candidates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1297

The early bactericidal activity of rifabutin in patients with pulmonary tuberculosis measured by sputum viable counts: a new method of drug assessment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1297

A multicentre study of the early bactericidal activity of anti-tuberculosis drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1297

The early bactericidal activity of a low-clearance liposomal amikacin in pulmonary tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1297

Sources of variation in studies of the early bactericidal activity of antituberculosis drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1297

A reiterative method for calculating the early bactericidal activity of antituberculosis drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1297

Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1297

Measurement of sputum Mycobacterium tuberculosis messenger RNA as a surrogate for response to chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1297

Inhibition of isoniazid-induced expression of Mycobacterium tuberculosis antigen 85 in sputum: potential surrogate marker in tuberculosis chemotherapy trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1297

Treatment of multidrug-resistant pulmonary tuberculosis with interferon-gamma via aerosol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1297

Treatment of refractory disseminated nontuberculous mycobacterial infection with interferon gamma. A preliminary report

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1297

Interleukin 12 (IL-12) is crucial to the development of protective immunity in mice intravenously infected with mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1297

Interleukin-12 (IL-12) augments cytolytic activity of natural killer cells toward Mycobacterium tuberculosis-infected human monocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1297

The effect of thalidomide on the pathogenesis of human immunodeficiency virus type 1 and M. tuberculosis infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1297

Pentoxifylline therapy in human immunodeficiency virus-seropositive persons with tuberculosis: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1297

Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1297

Early bactericidal and sterilizing activities of ciprofloxacin in pulmonary tuberculosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.8.1297

10.1517/13543784.12.8.1297

21 January 2018

Identifiers

DOI

1 reference

7 August 2017

1 reference

PubMed ID

12882618